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Abstract
Background: Youth with type 1 diabetes (T1D) have normal or elevated High-Density
Lipoprotein Cholesterol (HDL-C), however, the function of HDL, partly mediated by
the HDL proteome, may be impaired. Metformin can be used as an adjunct therapy in
youth with T1D, but its effects on the HDL proteome are unknown.
Objective: To determine the effect of metformin on the HDL proteome.
Subjects: Youth (12–20 years old) with T1D who had a BMI > 90th percentile,
HbA1c > 8.0% and Tanner stage 5.
Methods: Double-blinded, placebo-controlled randomized sub-study. We examined
the effects of metformin (n = 25) or placebo (n = 10) after 6 months on HDL proteome.
Changes in HDL proteins were measured by data-independent acquisition (DIA) mass
spectrometry and compared between treatment groups. As a secondary outcome,
associations between proteins of interest and the most studied function of HDL, the
cholesterol efflux capacity (CEC), was examined.
Results: The relative abundance of 84 HDL-associated proteins were measured. Two
proteins were significantly affected by metformin treatment, peptidoglycan recognition protein 2 (PGRP2; +23.4%, p = .0058) and alpha-2-macroglobulin (A2MG; +29.8%,
p = .049). Metformin did not significantly affect CEC. Changes in affected HDL proteins did not correlate with CEC.
Conclusions: Despite having little effect on HDL-C , metformin increased PGRP2
and A2MG protein on HDL in youth with T1D, but had no significant effect on CEC.
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provided the original work is properly cited.
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Further studies are needed to understand the impact of PGRP2 and A2MG on other
HDL functions.
KEYWORDS

cholesterol efflux, high-density lipoprotein, metformin, proteomics, type 1 diabetes
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BAC KG RO U N D

a double-blind, placebo-controlled clinical trial assessing metformin
usage as an adjunct therapy in obese adolescents with T1D. The de-

Type 1 diabetes (T1D) is associated with an increased risk of cardio-

sign and the results of the main clinical trial have been previously

vascular disease (CVD).1 This CVD risk is evident even in children with

described.11 In summary, this trial was conducted in 26 clinical sites

T1D and can manifest as increased carotid intima-media thickness,

of the T1D Exchange Clinic Network. Eligibility criteria for inclusion

increased pulse wave velocity, and decreased brachial artery disten-

in this trial included: age 12–20 years old, diagnosis of T1D, on treat-

sibility.2 Among the main risk factors that contribute to CVD risk are

ment with insulin for at least 1 year, BMI at or above the 85th per-

dyslipidemia, obesity, insulin resistance and poor glycemic control.1

centile based on CDC growth charts, total daily insulin dose of at

Dyslipidemia has traditionally been defined as low HDL-cholesterol

least 0.8 units/kg/day, HbA1c values at enrollment of 7.5%–10.0%

(HDL-C), elevated triglycerides (TG), and high LDL-cholesterol (LDL-C).

and checking blood glucose at least three times a day. A total of 140

The relationship between HDL-C and CVD risk has been somewhat

adolescents (aged 12.1–19.6 years old) were enrolled in this study.

enigmatic. While epidemiological studies clearly demonstrate an inverse correlation with CVD outcomes, pharmacological manipulation
of HDL-C has repeatedly failed to produce clinical benefit. Recent ev-

2.1 | Participants

idence suggests that the function of HDL is not directly linked to its
cholesterol content, therefore the presence of dysfunctional HDL may

For the current proteomic project, our inclusion criteria included

not be accounted for in the traditional HDL-C measure.3-5

participants with T1D who participated in the “T1D Exchange

The functions of HDL are driven by the protein and lipid compo-

Clinic Network Metformin RCT Study Group” trial and had a base-

nents that constitute the complex HDL particle. One of the main func-

line BMI > 90th percentile, HbA1c > 8.0% and were Tanner stage

tions of HDL is the reverse transport of cholesterol from the arteries to

5. Those criteria were selected in an effort to the minimize poten-

the liver, which initiates with the efflux of cholesterol from peripheral

tial effects of different stages of pubertal development on protein

tissues. This is often measured using an in vitro assay of cholesterol

cargo of HDL. We selected heavier participants and those with sub-

efflux capacity (CEC) and has been associated with cardiovascular

optimal glycemic control, given the expected lower insulin sensitiv-

events.6 HDL is also involved in atherosclerosis prevention by inter-

ity and potentially enhanced benefit from metformin treatment. Of

fering with coagulation, inflammation, and the complement pathway.7

the eligible participants, the core lab randomly selected 25 partici-

Our group has previously published that youth with T1D have lower

pants with T1D who were treated with metformin for 6 months and

CEC compared to healthy controls.3 Furthermore, we have shown that

matched them for age and sex with 10 participants with T1D treated

youth with T1D have smaller size HDL, which correlated with markers

with placebo for 6 months.

of insulin sensitivity,3 and less cholesterol distributed as large buoyant

The T1D Exchange Biobank studies are governed by individual

HDL-C on fast protein liquid chromatography, which correlated with

site institutional review boards. Qualifying participants provided

hyperinsulinemic-euglycemic clamp-assessed insulin sensitivity.8

consent or assent as age-appropriate and parents provided consent

Based on our previous work, we hypothesized that metformin,

for participants <18 years old.

which we previously demonstrated improves insulin sensitivity in
youth with T1D,9,10 could change the protein cargo on HDL and subsequently improve HDL function in youth with T1D. Our objective

2.2 | Clinical variables

was to determine the effect of metformin on the HDL proteome in
youth with T1D. As a secondary outcome, we examined whether the

Fasting blood samples were collected for analysis of a lipid profile

changes in protein abundance were associated with changes in the

(total cholesterol, high-density lipoprotein cholesterol [HDL-C], low-

CEC, as an indicator of HDL function.

density lipoprotein cholesterol [LDL-C], and triglycerides [TG] at a
central laboratory (Northwest Lipid Research Laboratories). HbA1c

2
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was measured with an automated glycohemoglobin analyzer (HLC-
723G8, Tosoh Bioscience). Dual-energy x-ray absorptiometry (DXA)
scans were done to assess % body fat. BMI percentile was calculated

This project utilized blood samples that were collected during the

using the childs package in r, using the 2000 CDC growth charts as

“T1D Exchange Clinic Network Metformin RCT Study Group” trial,

a reference.12

|
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2.3 | Proteomics experiments
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discovery rate (FDR) analysis function.16 MS/MS data were searched
in the NCBI Homo Sapiens of the Uniprot-Sprot database containing

The preparation of serum samples for the proteomics experiments

20,316 entries (downloaded on June 2, 2015). Carbamidomethylation

was performed as previously described.13,14 In brief, (1) purification

was set as a fixed modification on cysteine and trypsin was selected

of HDL from serum using size-exclusion chromatography; (2) pooling

as the enzyme. Variable peptide modifications included only methio-

of all the HDL containing fractions; (3) application of lipid-binding

nine (M) oxidation. Other search parameters used were instrument

resin to pooled HDL; (4) washing of HDL on the resin in order to

(TripleTOF 6600), ID Focus (Biological modifications), search ef-

remove contaminating proteins; (5) digestion of resin-bound HDL

fort (Thorough), false discovery rate (FDR) analysis (Yes), and user-

with trypsin (overnight 37°C); (6) washing of the resin in order to col-

modified parameter files (No). The proteins were inferred based on

lect tryptic peptides; (7) reduction and carbamidomethylation (DTT

the ProGroupTM algorithm, which is associated with the ProteinPilot

and iodoacetamide, respectively); and (8) desalting of samples using

software. The detected protein threshold in the software was set at

ZipTips. The samples were dried for proteomics analysis by using a

1% FDR. Peptides were defined as redundant if they had identical

nano Acquity UPLC coupled with a TripleTOF 6600 mass spectrom-

amino acid sequence, cleavage site(s), and modification.

eter (MS).

For the label-free SWATH (sequential window acquisition of all

As a first step, we established a library of all HDL proteins de-

theoretical fragment ion spectra) quantification, data from each

tectable by MS for the analysis of a sample pool from all the par-

sample was pre-processed by PeakView 2.1 (Sciex), with the default

ticipants (with an equal amount of proteins combined). The pooled

settings: (1) Peptide filter: # of peptides per protein: 6; peptide confi-

sample was analysed in data-dependent acquisition (DDA) mode.

dence threshold: 99%; # of transitions per peptide: 6; FDR threshold:

Then, we ran each sample individually via label-
free Sequential

1%; (2) Extracted ion chromatogram (XIC) Options: XIC extraction

Window Acquisition of All Theoretical Mass Spectra (SWATH) data-

window (min): 5; XIC width (ppm): 75. The retention time was cali-

independent acquisition (DIA) to quantify each of these proteins in

brated by selecting 6 peptides with retention time across the whole

the samples. Specifically, the peptides in each sample were dissolved

HPLC gradient. The peak of each transition produced was then

into 20 µl of 0.1% formic acid. For spectra library generation, the

manually checked and curated, with only transitions detected in all

pooled sample was loaded onto a C18 Trap column (Waters Acquity

samples and showing signal to noise (S/N) >10 chosen for peak area

UPLC Symmetry C18 NanoAcquity 10 K 2G V/M, 100 A, 5 μm,

calculation. The peptide response was then calculated as the sum

180 μm x 20 mm) at 15 µl/min for 4 min. Peptides were separated

of all ion intensity for all curated transitions. The sum of response

with an analytical column (Waters Acquity UPLC M-Class, peptide

from all curated peptides in each protein was used for protein level

BEH C18 column, 300 A, 1.7 μm, 75 μm x 150 mm) which had a

quantification. The intensity of the proteins was then normalized to

controlled temperature at 40°C. The flow rate was 400 nl/min. A

the total ion intensity of each sample, with the ratio of protein rep-

60-min gradient of buffer A (2% ACN, 0.1% formic acid) and buffer

resenting the protein level in each sample.

B (0.1% formic acid in ACN) was used for separation: 1% buffer B
at 0 min, 5% buffer B at 1 min, 45% buffer B at 35 min, 99% buffer
B at 37 min, 99% buffer B at 40 min. The gradient went back to 1%

2.5 | Cholesterol efflux assay

buffer B to equilibrate the column for 20 min. The TripleTOF 6600
mass spectrometer had an ion spray voltage of 2.3 kV, GS1 5 psi,

In order to determine whether changes in the HDL-bound proteins

GS2 0, CUR 30 psi and an interface heater temperature of 150°C.

of interest are associated with changes in the HDL function, we

The mass spectra were recorded with Analyst TF 1.7 software in the

measured the CEC of HDL as previously described by our group.3

DDA mode. Each cycle consisted of a full scan (m/z 400–1800) and

In summary, the HDL-CEC assays were performed using the mu-

fifty (IDAs; m/z 100–1800) in the high sensitivity mode with a 2+ to

rine macrophage cell line, J774, as per published methods.17-19

5+ charge state. Rolling collision energy was used. For the SWATH

Briefly, 3 x 105 J774 cells/well were plated and radiolabeled for

acquisition, each of the samples was injected individually into the

24 h with 2 µCi of 3H-cholesterol/ml. ATP-binding cassette trans-

same NanoUPLC-MS/MS system but acquired by repeatedly cycling

porter A1 (ABCA1) was up-regulated by incubation with 0.3 mmol/L

through 32 consecutive 25-Da precursor isolation windows, gener-

8-(4-chlorophenylthio)-c AMP for 16-hours. ApoB-depleted serum

ating time-resolved fragment ion spectra for all the analytes detect-

(2.8%) from participants was added to the efflux medium for 4 h.

able within the 400–1200 m/z precursor range.

Liquid scintillation counting was then added to quantify the efflux of radioactive cholesterol from the cells. Efflux was calculated

2.4 | Proteomics data analysis

using the standard formula: (µCi of 3H-cholesterol in media containing 2.8% apoB-depleted participant plasma-µCi of 3H-cholesterol
in plasma-free media / µCi of 3H-cholesterol in media containing

In order to generate the spectra library, raw mass spectra files after

2.8% apoB-depleted pooled control plasma-µCi of 3H-cholesterol in

DDA acquisition of the pooled sample were submitted for com-

pooled control plasma-free media). The pooled plasma control was

bined searches using Protein Pilot version 5.0 software (Sciex) utiliz-

obtained from five healthy adult volunteers and all assays were per-

ing the Paragon and Progroup algorithms15 and the integrated false

formed in duplicates run at the same time.

4 of 9

|

GOURGARI et al.

2.6 | Statistical analysis

samples. This library allowed for reliable detection of the relative
abundance of 84 different HDL-associated proteins. The Mann–

The distributions of all variables were examined prior to analysis.

Whitney test was used to screen measured percent changes in pro-

Descriptive statistics reported include frequencies and percent-

tein abundance among treatment groups to identify likely affected

ages for categorical variables, means and standard deviations for

proteins (Table S1). This initial screen-detected differences in av-

normally distributed continuous variables, and medians and percen-

erage percent change between placebo and metformin groups for

tiles for non-normally distributed continuous variables. To compare

six proteins: A2MG (Alpha-2-macroglobulin), KLKB1 (Kallikrein B1),

groups, either the chi-square test or Fisher's exact test was used for

ITIH4 (Inter-alpha-trypsin inhibitor heavy chain H4), A2AP (Alpha

categorical variables, and either the Mann-Whitney test or t-tests

2-antiplasmin), PGRP2 (Peptidoglycan recognition protein), CO8G

were used for continuous variables. For the initial identification of

(Complement C8 Gamma Chain). These candidate proteins were

any proteins that changed significantly after 6 months of treatment

then subjected to statistical analysis of raw ion intensity measure-

(among a total of 84 HDL proteins), we used the Mann-Whitney test

ments by T-test. With this analysis, only PGRP2 (+23.4%, p = .0058)

to compare the % change in each protein in the metformin vs. the

and A2MG and alpha-2-macroglobulin (+29.8%, p = .049) displayed

placebo group. For further analysis of the selected proteins, we per-

statistically significant increases in ion intensity in response to

formed T-tests on ion intensity values test to confirm our results.

metformin treatment (Figure 1A,B) while no effect was seen for

Finally, partial least squares discriminant analysis (PLS-DA) with

placebo. The other four proteins were not significantly affected by

leave-one-out cross-validation was used to examine whether par-

metformin when analysed this way (Figure 1C-F ). To determine if

ticipants in the two treatment groups could be discriminated on the

the cumulative minor effects of metformin on the HDL proteome

basis of changes in the proteins. All analyses were performed using

could discriminate between treatment groups, partial least squares

R version 3.5.1 or GraphPad Prism version 8.3.0.

discriminant analysis (PLS-DA) was performed. Discrimination of
the treatment groups by changes in proteins was minimal (Figure 2)

3
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and the ROC AUC for this model was 0.6, only slightly better than

R E S U LT S

chance. In this analysis, A2MG contributed most to discrimination
between treatment groups (Table S2). In our analysis, we had iden-

3.1 | Study population

tified one outlier with a protein that could skew the data. We also
performed sensitivity analysis which indicated that removal of the

The participants in the two treatment groups did not differ in age,

outlier point did not impact the ultimate conclusion of the statistical

sex, or race and all were Tanner stage V at baseline (Table 1). Baseline

comparison.

(Table 2) and after 6 months (Table 3) HbA1c, plasma lipids, % body
fat and BMI were not significantly different between groups. In a
univariate analysis, the insulin dose was significantly different be-

3.3 | Effect of metformin on CEC

tween patients with T1D and HC (Tables 2 and 3).
To evaluate the possible impact of metformin on the most studied

3.2 | Effect of metformin on the HDL proteome

function of HDL, CEC was measured in all participants at baseline
and 6 months follow-up. CEC of apoB-depleted plasma from each
participant was measured using cholesterol-
loaded J774 mac-

Using a label-free SWATH mass spectrometry analysis, an HDL pro-

rophages stimulated with cAMP to upregulate ABCA1 expression.

teome quantification library was generated using a subset of HDL

There was no significant difference between treatment groups at
baseline or after 6 months of treatment with metformin or placebo

TA B L E 1 Demographics of participants treated with metformin
or placebo

Age (years)

Metformin
(n = 25)

Placebo
(n = 10)

p
Value

15.6 ± 1.6

15.5 ± 1.7

.87

(Figure 3).

4
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DISCUSSION

In this analysis, from age and sex-matched youth with T1D treated

Sex n (%)
Female

19 (76%)

7 (70%)

Male

6 (24%)

3 (30%)

Hispanic

3 (12%)

1 (10%)

Non-hispanic white

20 (80%)

8 (80%)

Other

2 (8%)

1 (10%)

.69

first time that metformin has an increase on the PRGP2 (peptidoglycan recognition protein 2 also known as N-acetylmuramoyl-L-alanine

Race/ethnicity n (%)

Data displayed are mean ± SD or n (%).

with metformin or placebo for 6 months, we demonstrate for the

1

amidase) and A2MG (Alpha-2-macroglobulin) proteins on HDL. The
effect of metformin on PGRP2 and A2MG could potentially influence HDL function and impact the cardiovascular health of T1D
patients receiving this treatment. In this sub-study, we did not perform further mechanistic experiments to understand how functions

|
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TA B L E 2 The biochemical and clinical
variables at baseline by group

5 of 9

Metformin (n = 25)

Placebo (n = 10)

Baseline

Baseline

p Value

HbA1c (%)

9.1 (8.4, 9.4)

8.9 (8.7, 9.1)

1

LDL-C (mg/dl)

112 (93, 128)

97 (96, 112)

.6479

VLDL-C (mg/dl)

15 (10.75, 21.75)

22 (16, 26.25)

.0783

HDL-C (mg/dl)

52 (44, 56)

49 (45, 59.25)

1

Triglyceride (mg/dl)

76 (56, 106)

110 (79, 132)

.0828

Total cholesterol (mg/dl)

178 (157, 206)

174 (167.3, 201.5)

1

DEXA (% body fat)

40 (36, 45)

39 (36, 42)

.9376

BMI (kg/m2)

30.1 (27.6, 33.0)

28.7 (26.9, 31.8)

.3034

BMI (percentile)

97.4 (94.5, 98.1)

97.0 (93.0, 97.4)

.3771

BMI Z-score

1.94 (1.60, 2.08)

1.88 (1.48, 1.94)

.3807

DEXA % fat

40 (36, 45)

39 (36, 42)

.9376

Waist circumference(cm)

94.9 (88.8, 104.0)

95.3 (91.0, 101.9)

.9273

Insulin dose (units/kg/day)

0.96 (0.85, 1.05)

1.21 (1.03, 1.38)

.0207

Note: Values are reported as median (25th %ile, 75th %ile). p-values were calculated using the
Mann-Whitney test.

TA B L E 3 The biochemical and clinical
variables at 6 months by group

Metformin (n = 25)

Placebo (n = 10)

6 months

6 months

HbA1c (%)

8.8 (8.0, 9.4)

9.0 (8.3, 9.9)

.3235

LDL-C (mg/dl)

113 (90, 122)

100 (92, 114)

.6919

VLDL-C (mg/dl)

14.5 (11.0, 20.0)

17.5 (12.0, 20.0)

.4591

HDL-C (mg/dl)

53.0 (44.0, 60.0)

47.5 (41.0, 56.8)

.3594

Triglyceride (mg/dl)

71.0 (54.8, 99.0)

88.5 (61.8, 98.0)

.4609

Total cholesterol (mg/dl)

179 (160, 193)

172 (157, 188)

.5838

DEXA (% body fat)

41 (37, 44)

40 (35, 43)

.6698

2)

p Value

30.1 (26.9, 32.7)

29.0 (26.6, 32.0)

.6275

BMI (percentile)

96.1 (94.5, 98.1)

95.7 (93.8, 97.8)

.7060

BMI z

1.76 (1.60, 2.07)

1.73 (1.55, 2.01)

.7149

DEXA % fat

41 (37, 44)

40 (35, 43)

.6698

Waist circumference(cm)

93.5 (88.9, 101.5)

92 (82.3, 105.3)

Insulin dose (units/kg/day)

0.82 (0.68, 0.95)

1.12 (0.92, 1.28)

BMI (kg/m

.7150
<.001

Note: Values are reported as median (25th %ile, 75th %ile). p-values were calculated using the Mann-
Whitney test.

of HDL might be affected by enrichment of the HDL molecule with

that PGRP2 was higher in the HDL of youth with T1D compared to

the PGRP2 and A2MG protein. However, we do demonstrate that

healthy controls. 20 This would suggest that the effect of metformin

it does not appear to involve cholesterol efflux activity, the most

shifts the level of this protein even further from the level of healthy

widely studied HDL function. While further experiments are needed

control participants rather than normalizing it toward the level of

to fully elucidate the mechanisms by which metformin alters PGRP2

healthy controls. We also have shown previously that PGRP2 was

and A2MG protein on HDL and how this may impact HDL function,

not associated with glycemic control in youth with T1D. 20 It is pos-

we discuss below how our findings relate to what is known about

sible that the percent change in PRGP2 may be more closely related

HDL-associated PRGP2 and A2MG and how this protein might con-

to other factors relative to the metformin use rather than glycemic

tribute to CVD risk.

control. In fact, the T1D-Metformin RCT trial did not show any sig-

In the current study, we found that HDL-associated PGRP2 in-

nificant impact of metformin on HbA1c.11 Overall, our findings sug-

creased significantly after metformin treatment while no change was

gest that metformin increases the PGRP2 and A2MG proteins on

observed in the placebo group. Our group has previously published

HDL and below we discuss the possible effects on metabolic and

6 of 9

|

GOURGARI et al.

(B)

(A)

(D)

(C)

F I G U R E 1 Effect of 6-month placebo
or metformin treatment on HDL-
associated proteins. Ion intensity values
detected by data-independent acquisition
(DIA) mass spectrometry analysis of size-
exclusion chromatography purified HDL
were compared for subjects receiving
placebo or metformin for 6 months. T-
tests were used for statistical comparison
between baseline and 6-month time
points within each treatment group. *
indicates p < .05; ** indicates p < .01; no
indicator is present where comparisons
are not statistically significant. A2MG:
alpha-2-macroglobulin, ITIH4: inter-
alpha-trypsin inhibitor heavy chain
family member 4, KLKB1: kallikrein B1,
A2AP: alpha-2-antiplasmin, PGRP2:
peptidoglycan-recognition protein 2, CO8:
complement 8

(F)

(E)

F I G U R E 2 Plot from PLS-DA for
protein changes by treatment group.
Partial least squares discriminant analysis
(PLS-DA) was used to determine if the
cumulative effects of metformin on
the HDL proteome could be used to
distinguish treatment groups. Mass
spectrometry ion intensities from all
84 quantified proteins were used as
input variables for the model. Rankings
of the top 10 weighted proteins from
components 1 and 2 are listed in
Table S2

cardiovascular health based on what is known so far about the func-

(PGRP1), which belongs to the same family of proteins, was found

tion of these proteins.

to be associated with atherosclerotic cardiovascular events in the

Interestingly, one study found that patients with the acute
coronary syndrome had lower expression of PGRP2 levels in HDL

Dallas Heart Study and participants with the highest levels of PGRP1
were >3 times more likely to develop CVD. 22

compared to patients with stable coronary disease, even though

Peptidoglycan recognition proteins are known to be responsi-

no difference was found when compared to HDL levels of healthy

ble for keeping a normal gut microbiome environment and protect

controls. 21 These patients were older men, with and without cor-

the host from inflammation and colitis. 23 PGRP2 is present in the

onary disease and only 1/30 participants had diabetes. It is likely

serum, the skin and the epithelial cells of the intestines.24 The ex-

that age, sex and diabetes status might further explain alterations of

pression of PGRP2 is highest in the liver, from where it is secreted in

PRGP2 levels in HDL. Also, the peptidoglycan recognition protein 1,

the blood, and PGRP2 expression is also induced by bacteria in the
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1.4

Baseline
6 months
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in restoring CEC might be different in certain patient populations
with a high degree of glycated HDL. Future studies can examine
the factors that affect the glycation of proteins of HDL in patients
with T1D and whether metformin or other diabetes drugs such as
insulin could restore the CEC of glycated forms of HDL in patients

1.0

with T1D. Further studies are needed to examine the exact role of
PRGP2 and A2MG on HDL function and whether metformin's effect

0.8
0.6

on gut microbiota affects the expression of PGRP2 in the intestine
and HDL.

Placebo

Metformin

F I G U R E 3 Effect of placebo or metformin on cholesterol
efflux capacity. Cholesterol efflux to apoB-depleted serum was
measured using cAMP-treated J774 macrophage cells loaded
with radiolabeled cholesterol. Efflux was normalized to a healthy
control sample pool. Data were analysed using repeated measures
two-way ANOVA with Sidak correction for multiple comparisons.
No indicator is present where comparisons are not statistically
significant

Of note, 3 of the 6 proteins on our initial screening are involved
in the coagulation pathway and formation of the fibrin clot: A2MG,
alpha-2-macroglobulin, KLKBI, Kallikrein B1, and A2AP, Alpha
2-
antiplasmin. These pathways are involved in the pathogenesis
of atherosclerosis and coagulation, which supports the hypothesis
that changes in these proteins could affect the anti-thrombotic HDL
function.32 Our group had also previously found that KLKB1 of HDL
was associated with lower CEC. 29 However, given that KLKBI and
A2AP proteins also increased in some participants in the placebo
group (Figure 1), we believe more research is needed to explore
whether metformin changes the anti-thrombotic function of HDL by

epithelial cells of all segments of the gastrointestinal tract. 23 There

altering the expression of the above proteins.

is growing evidence about the role of altered gut microbiota to pro-

Strengths of our study include the fact that we were able to

mote CVD via several mechanisms, such as altering lipid metabolism,

match participants that were treated with metformin or placebo in

playing a role in vascular dysfunction and hypertension, increasing

a double-blinded randomized fashion. All participants were over-

systemic inflammation, foam cell formation and insulin resistance. 25

weight and had similar glycemic control and pubertal stage. We

There is recent evidence that treatment with metformin not only al-

also have detailed HDL proteome data: The two-step size-exclusion

ters the gut microbiome but some of the beneficial effects of met-

chromatography and lipid interaction-based HDL purification and

formin could be due to the change in the gut microbiome. 26,27 It is

the SWATH-MS allowed us to have a very sensitive and robust

also known that the intestine has a significant contribution to the

label-free proteomic quantitation for multiple clinical samples. Our

production of HDL-C . 28 Based on the above, it is possible that met-

two-step approach to the proteomics data analysis included an ini-

formin alterations to the gut microbiome could be associated with

tial screening for metformin affected proteins based on percent

changes in the peptidoglycan protein expression of PRGP2 in the

change by treatment group and was followed up with direct com-

intestines and also on PRGP2 concentration on HDL.

parisons of candidate proteins by their detected ion intensities. This

We also found that A2MG increased after metformin. Our group

approach improved confidence in detected differences and reduced

has previously found that the A2MG protein of HDL was positively

the false discovery rate by filtering out weaker effects. Limitations

associated with calcified burden of coronary angiography, a marker

of this study include our small sample size and the lack of additional

of increased CVD risk. 29 Another group also found higher A2MG

HDL function assays or assays directly related to PGRP2 function

protein of HDL in patients with non-alcoholic fatty liver disease,

and the lack of directly measured insulin sensitivity. A limitation of

suggestive of increased fibrinogenesis activity.30 More research is

our HDL purification method is that it does not allow for analysis

needed to explore whether metformin changes the anti-thrombotic

of HDL subfractions which are commonly characterized by density

function of HDL by altering the expression of A2MG protein.

and isolated by ultracentrifugation.33 One advantage of our ap-

Our study did not find any effects of metformin on HDL efflux

proach over ultracentrifugation is that it purifies HDL under phys-

capacity, contrary to our hypothesis. A previous study by Matsuki

iological g forces and salt conditions resulting in less disruption of

et al31 showed that glycation of HDL reduced the CEC of HDL and

protein interactions on lipoproteins caused by extreme conditions

that metformin restored this defect in studies done in vitro, by pre-

experienced during ultracentrifugation.34,35 The downside is that

venting the glycation of HDL. One possible explanation for the dif-

size-exclusion chromatography by itself does not isolate pure HDL

ference with our findings is that the dose used for the in vitro studies

preparations and there is some contamination of non-lipoprotein-

was relatively higher and had a more potent effect than the dose

associated proteins (e.g. albumin and immunoglobulins). This is

that has been approved for use in humans. In addition, in our study,

overcome by our two-step isolation, which includes washing of li-

all patients had diabetes with a HbA1c well above target, and we

poproteins on a lipid-binding resin.13 Alternative approaches to the

thus assume that a certain degree of glycation of HDL was present

isolation of native HDL include immunoaffinity adsorption usually

in all of them. However, our study was not designed to look at the

by pulldown with anti-apolipoprotein A-I antibodies.36,37 This tech-

glycated forms of HDL. It is possible that the effect of metformin

nique produces clean HDL, but it is not known if some HDL-binding
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proteins can influence antibody interactions with HDL and this ap-

manuscript. Laura Pyle: Did the statistical analysis, reviewed and ed-

proach may exclude lipoproteins in the HDL size range which do not

ited the manuscript. Martin P. Playford: Did the cholesterol efflux ex-

contain apolipoprotein A-I. However, the goal for this pilot project

periments, reviewed and edited the manuscript. Junfeng Ma: Did the

was to provide an initial characterization of the effect of metformin

proteomics experiments, reviewed and edited the manuscript. Nehal

on the proteomic composition of HDL and identify associations with

N. Mehta: Reviewed and edited the manuscript. Alan T. Remaley:

changes in cholesterol efflux function. Even though we did not find

Conceptualization, development of the project, reviewed and edited

a significant change in CEC, it is possible this was due to our rela-

the manuscript. Scott M. Gordon: Conceptualization, development

tively small sample size or that the treatment did not have an impact

of the project, did the proteomics experiments, reviewed, edited and

on pre-beta HDL, the particle species predominantly responsible

approved the final manuscript.

for ABCA1-mediated cholesterol efflux.

38

Pre-beta HDL are small

discoidal particles composed of apolipoprotein A-I, phospholipid,

PAT I E N T C O N S E N T S TAT E M E N T

and free cholesterol, and they do not contain many other proteins.39

Patients gave consent to participate in the T1D-
E xchange

Therefore, effects observed in the HDL proteome are likely not

Metformin RCT.

reflective of changes to pre-beta particles. Although it is possible
that redistribution of apoA-I or other proteins among HDL subspe-

DATA AVA I L A B I L I T Y S TAT E M E N T

cies could occur even if no change in the total apoA-I protein was

Not applicable.

observed. However, this could not be detected without isolation of
distinct HDL subfractions. It is also possible that there may be in-

ORCID

teresting glycation modifications to HDL proteins that could impact

Evgenia Gourgari

https://orcid.org/0000-0002-5788-7955

particle functions and might be prevented or reversed by metformin,
but we were unable to examine these in the present analysis. Future
studies can further explore whether enrichment of HDL with PRGP2
could potentially alter HDL function.
In summary, we found a significant increase in the PGRP2 and
A2MG content of HDL in youth with T1D treated with metformin
compared to placebo by combining size-exclusion chromatography-
based HDL purification and SWATH-MS-based label-free proteomic
quantitation. Further studies are needed to explore whether this effect of metformin impacts other known functions of HDL such as
the anti-inflammatory or anticoagulant activity, and to also explore
potential novel functions arising from this interaction. With the recent rapid advancements in proteomics technologies, future studies
to investigate the factors that contribute to the glycation of HDL
proteins in patients with T1D and how those are impacted by metformin or other diabetes drugs will be of significant interest.
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